These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33758125)

  • 1. Genetic Risk Assessment for Atherosclerotic Cardiovascular Disease: A Guide for the General Cardiologist.
    Belanger MJ; Kelly EM; Tahir UA; Benson MD
    Cardiol Rev; 2022 Jul-Aug 01; 30(4):206-213. PubMed ID: 33758125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining European and U.S. risk prediction models with polygenic risk scores to refine cardiovascular prevention: the CoLaus|PsyCoLaus Study.
    de La Harpe R; Thorball CW; Redin C; Fournier S; Müller O; Strambo D; Michel P; Vollenweider P; Marques-Vidal P; Fellay J; Vaucher J
    Eur J Prev Cardiol; 2023 May; 30(7):561-571. PubMed ID: 36652418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?
    Hadley TD; Agha AM; Ballantyne CM
    Curr Atheroscler Rep; 2021 Apr; 23(6):28. PubMed ID: 33791884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.
    D'Erasmo L; Minicocci I; Di Costanzo A; Pigna G; Commodari D; Ceci F; Montali A; Brancato F; Stanca I; Nicolucci A; Ascione A; Galea N; Carbone I; Francone M; Maranghi M; Arca M
    J Am Heart Assoc; 2021 May; 10(9):e018932. PubMed ID: 33890476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of incident atherosclerotic cardiovascular disease with polygenic risk of metabolic disease: Analysis of 3 prospective cohort studies in Korea.
    Song H; Koh Y; Rhee TM; Choi SY; Kang S; Lee SP
    Atherosclerosis; 2022 May; 348():16-24. PubMed ID: 35390551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic background as a risk factor for atherosclerotic cardiovascular disease: A protocol for a nationwide genetic case-control (CV-GENES) study in Brazil.
    Alves de Oliveira H; de Menezes Neves PDM; de Figueiredo Oliveira GB; Moreira FR; Pintão MCT; Rocha VZ; de Souza Rocha C; Katz VN; Ferreira EN; Rojas-Málaga D; Viana CF; da Silva FF; Vidotti JJ; Felicio NM; de Araújo Vitor L; Cesar KG; Araújo da Silva C; de Oliveira Alves LB; Avezum Á
    PLoS One; 2024; 19(3):e0289439. PubMed ID: 38478535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia.
    Trinder M; Li X; DeCastro ML; Cermakova L; Sadananda S; Jackson LM; Azizi H; Mancini GBJ; Francis GA; Frohlich J; Brunham LR
    J Am Coll Cardiol; 2019 Jul; 74(4):512-522. PubMed ID: 31345425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments.
    Busby GB; Kulm S; Bolli A; Kintzle J; Domenico PD; Bottà G
    Nat Commun; 2023 Nov; 14(1):7105. PubMed ID: 37925478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Three Atherosclerotic Cardiovascular Disease Risk Scores With and Without Coronary Calcium for Predicting Revascularization and Major Adverse Coronary Events in Symptomatic Patients Undergoing Positron Emission Tomography-Stress Testing.
    Anderson JL; Le VT; Min DB; Biswas S; Minder CM; McCubrey RO; Knight S; Horne BD; Mason S; Lappe DL; Muhlestein JB; Knowlton KU
    Am J Cardiol; 2020 Feb; 125(3):341-348. PubMed ID: 31806210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast Arterial Calcification: A Potential Biomarker for Atherosclerotic Cardiovascular Disease Risk?
    Yoon YE; Yun B; Kim KM; Suh JW
    Curr Atheroscler Rep; 2021 Mar; 23(5):21. PubMed ID: 33772359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
    Gallo A; Pérez de Isla L; Charrière S; Vimont A; Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; Moulin P; Bruckert E; Mata P; Béliard S;
    JACC Cardiovasc Imaging; 2021 Dec; 14(12):2414-2424. PubMed ID: 34274263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease.
    Smith JL; Schaid DJ; Kullo IJ
    Curr Atheroscler Rep; 2023 Jun; 25(6):323-330. PubMed ID: 37223852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction.
    Nurmohamed NS; Kraaijenhof JM; Mayr M; Nicholls SJ; Koenig W; Catapano AL; Stroes ESG
    Eur Heart J; 2023 May; 44(18):1594-1607. PubMed ID: 36988179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of atherosclerotic cardiovascular risk in early childhood.
    Ferraro S; Benedetti S; Mannarino S; Marcovina S; Mario Biganzoli E; Zuccotti G
    Clin Chim Acta; 2024 Jan; 552():117684. PubMed ID: 38016628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Predisposition of Atherosclerotic Cardiovascular Disease in Ancient Human Remains.
    Wurst C; Maixner F; Paladin A; Mussauer A; Valverde G; Narula J; Thompson R; Zink A
    Ann Glob Health; 2024; 90(1):6. PubMed ID: 38273870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from Lipid-Lowering Therapy?
    Arnold N; Koenig W
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):627-635. PubMed ID: 33156471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
    Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
    Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A performance guide for major risk factors control in patients with atherosclerotic cardiovascular disease in Taiwan.
    Li YH; Chen JW; Lin TH; Wang YC; Wu CC; Yeh HI; Huang CC; Chang KC; Wu CK; Chen PW; Huang CW; Chen ZC; Chang WT; Huang WC; Wang CY; Lee MY; Chao AC; Fu WR; Tsai LK; Tang SC; Chan HL; Yang YC; Wu YW; Hwang JJ; Lin JL
    J Formos Med Assoc; 2020 Mar; 119(3):674-684. PubMed ID: 31113748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography.
    Lee WJ; Chuang HN; Chen YM; Liang KW; Tung H; Chen JP; Lee IT; Wang JS; Lin CH; Lin HJ; Sheu WH; Lee WL; Hsiao TH
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.